SCHEMBL10065833

SCHEMBL10065833

O=C(O)Cc1n[nH]c(=O)c2nnccc12

nearest known ligand 0.57

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.57
KDM4E B2RXH2 1/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
ALDH1A1 P00352 2/20 0.38
PARP1 P09874 5/20 0.35
AR P10275 1/20 0.35
PRMT5 O14744 3/20 0.34
WDR77 Q9BQA1 2/20 0.34
TSHR P16473 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10065832 0.88 LMNA (0.57) LMNAKDM4EPOLBSMN1; SMN2ALDH1A1
SCHEMBL15217613 0.80 SMN1; SMN2 (0.45) LMNASMN1; SMN2ALDH1A1PRMT5WDR77
SCHEMBL16561506 0.75 LMNA (0.48) LMNAKDM4EPOLBSMN1; SMN2ALDH1A1
SCHEMBL18265861 0.75 LMNA (0.48) LMNAKDM4EPOLBSMN1; SMN2ALDH1A1
SCHEMBL30151141 0.73 LMNA (1.00) LMNAKDM4EPOLBSMN1; SMN2ALDH1A1
SCHEMBL5717747 0.73 LMNA (1.00) LMNAKDM4EPOLBSMN1; SMN2ALDH1A1
SCHEMBL19199613 0.73 LMNA (0.66) LMNAKDM4EPOLBSMN1; SMN2ALDH1A1
SCHEMBL360658 0.73 LMNA (0.53) LMNAKDM4EPOLBSMN1; SMN2ALDH1A1
SCHEMBL10065472 0.71 LMNA (0.54) LMNAKDM4EPOLBSMN1; SMN2ALDH1A1
SCHEMBL15217609 0.70 SMN1; SMN2 (0.45) LMNAPOLBSMN1; SMN2ALDH1A1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170319584-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-11-09 US disclosed
US-20170216291-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2017-08-03 US disclosed
EP-3192796-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF The Trustees of Columbia University in the City of New York (US) 2017-07-19 EP disclosed
US-9650383-B2 Aldose reductase inhibitors and uses thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-05-16 US disclosed
EP-2593456-B1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF UNIV COLUMBIA (US) 2016-11-30 EP disclosed
US-20150072989-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-03-12 US disclosed
WO-2012009553-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170216291-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 LMNA 1361/4885KDM4E 1917/4885POLB 1462/4885
US-20170319584-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 LMNA 1361/4885KDM4E 1917/4885POLB 1462/4885
US-20150072989-A1 ALDOSE REDUCTASE INHIBITORS AND USES THEREOF ALDOA, AKR1B1, AKR1C2 LMNA 1361/4885KDM4E 1917/4885POLB 1462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.